TITLE

Evaluation of Safety and Anti-obese Activity of a Polyherbal Formulation -- Simlim Capsule

AUTHOR(S)
Shah, Bijal N.; Soni, Hardik K.; Patel, Ghanshyam R.; Patel, Pooja D.; Paranjape, Archana N.
PUB. DATE
May 2013
SOURCE
International Journal of Pharmaceutical & Phytopharmacological R;
SOURCE TYPE
DOC. TYPE
Article
ABSTRACT
Obesity is one the most common and now considered as global health problem which triggers many other metabolic disorders. In the present study, a polyherbal formulation - Simlim Capsule was evaluated for its anti-obesity activity in high fat diet (HFD) induced male Wistar albino rats. It was also compared with modern medicine available in the market i.e. Orlistat. It was revealed that HFD elicited significant increase in body weight, daily food intake, and serum levels of glucose, total cholesterol, LDL Cholesterol, VLDL cholesterol, Triglycerides, ALT and AST level. Treatment with Simlim Capsule in dose of 180mg/kg (p.o) inhibited rise in body weight and daily food intake which shows its hypophagic activity. It also reduced lipid level such as triglyceride, LDL, VLDL and serum glucose levels while high density lipoproteins (HDL) was found increased which indicates its cardio protective activity. It has also significantly reduced ALT and AST level in serum. Histopathological changes of liver like hepatic steatosis induced by high fat diet was overcame by Simlim capsule and results were found comparable with Orlistat. Hence, it was concluded that Simlim Capsule is having anti-obesity activity by reducing cholesterol and triglyceride content, thus helping to reduce weight.
ACCESSION #
94508108

 

Related Articles

  • Xenical. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p809 

    An encyclopedia entry for "Xenical" is presented. It refers to a brand name of a drug pharmacologically called orlistat. The drug Xenical is commonly used for the treatment of patients who are exhibiting symptoms of mild to moderate obesity and more on those who are already on the stage of...

  • Choosing the Right Weight Loss Medication for Your Patient Requires Careful Consideration. Still, Christopher // Bariatric Times;Dec2015, Vol. 12 Issue 12, p3 

    The author discusses how to match a patient with the right weight loss medication given his risk, medical history and preferences. He cites the 5 Food and Drug Administration (FDA) approved pharmacotherapy options for treating obesity including phentermine, orlistat and phentermine/topiramate...

  • SECTION 7 METABOLIC DISORDERS.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p131 

    The article offers information on several drugs for the treatment of obesity. The Belviq weight-loss medication from pharmaceutical firm Eisai Co. Ltd. should be used together with a reduced-calorie diet and weight maintenance to treat obesity. Obese patients are advised to take the Qsymia...

  • Obesity Drug Inhibits Prostate Tumor Growth.  // Ascribe Newswire: Medicine;3/22/2004, p41 

    The Burnham Institute's Jeffrey Smith, has discovered that orlistat, commonly prescribed as an anti-obesity drug orlistat, marketed as XenicalT, has a positive side-effect: it inhibits cancer growth. Smith made this discovery using an activity-based proteomics screening technique developed in...

  • The uphill battle facing antiobesity drugs. Daubresse, M; Alexander, G C // International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377 

    The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and...

  • Safety profile of orlistat: results of a prescription-event monitoring study. Acharya, N. V.; Wilton, L. V.; Shakir, S. A. W. // International Journal of Obesity;Nov2006, Vol. 30 Issue 11, p1645 

    Introduction:Orlistat, the first of a new class of drugs for the treatment of obesity, was launched in the UK in December 1998. The prescribing information recommends that treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a specified loss of...

  • A one-of-a-kind anti-obesity drug reaches the market. Cerrato, Paul L. // RN;Jun99, Vol. 62 Issue 6, p80 

    Reports on the use of the lipase inhibitor orlistat in treating obesity. Mechanism of action; Adverse effects of the drug.

  • Hydroxycut (herbal weight loss supplement) Induced Hepatotoxicity: A Case Report and Review of Literature. Sharma, Tarun; Wong, Linda; Tsai, Naoky; Wong, Russell D. // Hawaii Medical Journal;Aug2010, Vol. 69 Issue 8, p188 

    Use of supplement and alternative drugs continues to thrive and is becoming an increasing cause of concern since many of these substances may have unexpected or unexplained medical consequences. We present below the first reported case of hepatotoxicity from Hydroxycut in Hawai'i.

  • Aristolochic Acid and Renal Toxicity. O'Mathúna, Dónal P. // Alternative Medicine Alert;Nov2008, Vol. 11 Issue 11, p126 

    The article focuses on aristolochic acid nephropathy (AAN) as a cause of renal toxicity. Several cases of renal failure attributed to the exposure with a herbal slimming remedy were discussed. Herbs containing aristolochic acid are interchanged and used with other botanicals in China and India....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics